Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

Han weidong20 enrolled

Overview

To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Autologous CIK transfusion within 3 days post CD20 antibody treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lymphomas

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy Exclusion Criteria: \- to refuse the therapy and need not tolerate the therapy

Outcomes

Primary Outcomes

disease free survival

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.